Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Cancer of Colon Clinical Trial

Official title:

Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05553080
• Other study ID #: Soh-Med-22-09-14
• Status: Completed
• Start date: January 1, 2022
• Est. completion date: December 1, 2022

Study information

• Verified date: October 2022
• Source: Sohag University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.

Description:

colorectal carcinoma is an aggressive malignant tumor. It has high incidence of cancer-related morbidity and mortality. the malignant potential of a given neoplasm is based mainly on its ability to invade the surrounding vasculature and reach to distant sites, the latter is called metastasis. in order to metastasize to distant sites, the neoplastic cells must re-arrange the intracellular actin filaments into well formed intracellular assembly which enable the neoplastic cells to reach to distant sites. Fascin-1 is an actin binding protein, it is involved in reconstruction of actin assembly. fortunately, Fascin-1 could be blocked by newly developed medications, blocking of Fascin-1 may limit the metastasis of colorectal carcinoma. in current study the investigators detect Fascin-1 in colorectal carcinoma by immunohistochemical approach, then they correlated different levels of Fascin-1 expression to tumor clinical and pathological criteria as patients' ages, sexes, tumor stages, nodal metastasis, vascular and per-ineural invasions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 1, 2022
• Est. primary completion date: September 30, 2022
• Gender: All
• Age group: 30 Years to 90 Years

Eligibility

Inclusion Criteria:

• All cases of colorectal carcinoma.

Exclusion Criteria:

• cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy.

• Patients with preopoerative history of chemo or radiotherapy.

• Patients with poor clinical data.

Related Conditions & MeSH terms

• Cancer of Colon
• Colonic Neoplasms
• Colorectal Neoplasms

Intervention

Genetic:
• Immunohistochemistry
immunohistochemical staining of colorectal carcinoma specimens by anti human fascin antibody.

Locations

Country	Name	City	State
Egypt	Maisa Hashem Mohammed	Sohag
Egypt	Sohag faculty of medicine	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1	correlation of different levels of Fascin-1 expression to patients' ages, sexes, tumor stage, nodal metastasis, vascular and perineural invasion.	September , 2022